<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135212</url>
  </required_header>
  <id_info>
    <org_study_id>A657-BR-CT-302</org_study_id>
    <nct_id>NCT01135212</nct_id>
  </id_info>
  <brief_title>The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daegu Catholic University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A medical center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate and compare the efficacy and safety of&#xD;
      Fimasartan (60mg / 120mg) with Candesartan(8mg) in patients with mild to moderate&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, Candesartan controlled, parallel group comparison clinical study&#xD;
      to evaluate the antihypertensive efficacy and safety of Fimasartan in patients with mild to&#xD;
      moderate hypertension Approximately 288 patients will be enrolled in 10 centers in South&#xD;
      Korea. This study has planned 5 visits during 14 weeks (placebo run-in period 2 weeks,&#xD;
      treatment period 12 weeks). All of the subjects who agreed to participate in this study and&#xD;
      gave the written informed consent voluntary are assessed the exclusion and inclusion criteria&#xD;
      and receive the investigational product(placebo) at screening visit.&#xD;
&#xD;
      During more than 14 days of placebo run-in period, subjects have to stop the previous&#xD;
      anti-hypertension drug. After 2 weeks, subjects are assessed the final eligibility and&#xD;
      randomized into one of 3 groups(Fimasartan 60mg, Fimasartan 120mg, Candesartan 8mg) at&#xD;
      baseline visit. Subjects take physical and laboratory tests and receive the investigational&#xD;
      products per 4weeks during treatment period (12weeks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sitting Diastolic Blood Pressure</measure>
    <time_frame>12weeks from baseline visit</time_frame>
    <description>To compare the difference of Sitting Diastolic Blood Pressure at 12 weeks from baseline visit Fimasartan 60mg with Candesartna 8mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sitting DBP</measure>
    <time_frame>at 12weeks from Baseline visit</time_frame>
    <description>To compare the difference of Sitting Diastolic Blood Pressure at 12 weeks from baseline visit Fimasartan 120mg with Candesartna 8mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SittingDBP</measure>
    <time_frame>at 4, 8 weeks from baseline visit</time_frame>
    <description>To compare the difference of Sitting Diastolic Blood Pressure at 4, 8 weeks from baseline visit Fimasartan 60/120mg with Candesartna 8mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sitting Systolic Blood Pressure</measure>
    <time_frame>at 4,8,12 weeks from baseline visit</time_frame>
    <description>To compare the difference of Sitting Systolic Blood Pressure at 4,8,12 weeks from baseline visit Fimasartan 60mg/120mg with Candesartna 8mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder ratio</measure>
    <time_frame>at 12weeks from baseline visit</time_frame>
    <description>To compare the ratio or responder(SiDBP&lt;90mmHg or difference of SiDBP&gt;10mmHg from baseline) at 12 weeks Fimasartan 60mg/120mg with Candesartna 8mg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan 60mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one tablet of Fimasartan 60mg once a day in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 120mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one tablet of Fimasartan 120mg once a day in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan 8mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one tablet of Candesartan 8mg once a day in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan 60mg</intervention_name>
    <description>Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.</description>
    <arm_group_label>Fimasartan 60mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan 120mg</intervention_name>
    <description>Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.</description>
    <arm_group_label>Fimasartan 120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil</intervention_name>
    <description>Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.</description>
    <arm_group_label>Candesartan 8mg</arm_group_label>
    <other_name>Atacand 8mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who agreed to participate in this study and submitted the written informed&#xD;
             consent&#xD;
&#xD;
          2. Subjects aged 19 to 75 years&#xD;
&#xD;
          3. Mild to moderate essential hypertension subjects who are measured more 90mmHg, less&#xD;
             than 110mmHg of sitting diastolic blood pressure (SiDBP) at baseline(day 0).&#xD;
&#xD;
          4. Subjects who considered to understand this study , be cooperative, and able to be&#xD;
             followed-up whole of the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe hypertension patients; more 110mmHg of SiDBP and/or more 180 mmHg of Sitting&#xD;
             systolic blood pressure (SiSBP)&#xD;
&#xD;
          2. Patients with secondary hypertension&#xD;
&#xD;
          3. Patients with significant investigations - abnormal renal function (Creatinine more&#xD;
             than upper limit of normal), abnormal liver function (AST, ALT more 2 times than upper&#xD;
             normal), moderate fatty lever needed medication&#xD;
&#xD;
          4. Patients with hypotension who has sign and symptom&#xD;
&#xD;
          5. Patients with surgical and medical disease it is able to be affect to absorption,&#xD;
             distribution, metabolism, excretion&#xD;
&#xD;
          6. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c &gt; 9%,&#xD;
             regimen change of oral hypoglycemic agent, using insulin)&#xD;
&#xD;
          7. Patients with severe heart disease, ischemic heart disease within 6months, peripheral&#xD;
             vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary&#xD;
             Artery Bypass Graft (CABG)&#xD;
&#xD;
          8. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter&#xD;
             or other significant arrhythmia&#xD;
&#xD;
          9. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary&#xD;
             artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral&#xD;
             valve disease&#xD;
&#xD;
         10. Patients with severe cerebrovascular disease&#xD;
&#xD;
         11. Patients with wasting disease, autoimmune disease, connective tissue disease at&#xD;
             present and/or previous.&#xD;
&#xD;
         12. Patients with known severe or malignancy retinopathy&#xD;
&#xD;
         13. Patients with hepatitis B or C or HIV positive reaction&#xD;
&#xD;
         14. Patients who have a story or evidence of alcohol or drug abuse within 2years&#xD;
&#xD;
         15. Patients who are measured the mean difference of mean blood pressure of both arm under&#xD;
             SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit&#xD;
&#xD;
         16. Patients with history of allergic reaction to any angiotensin II antagonist&#xD;
&#xD;
         17. Patients with any chronic inflammation disease needed to chronic inflammation therapy&#xD;
&#xD;
         18. Childbearing and breast-feeding women&#xD;
&#xD;
         19. Female who plan to become pregnancy or have a possibility of pregnancy but don't&#xD;
             prevent conception with acknowledged methods&#xD;
&#xD;
         20. Patients who took medicine within 12 weeks from screening visit or is going on the&#xD;
             progress of other clinical trial&#xD;
&#xD;
         21. Subject who are judged unsuitable to participate in this study by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ShungChull Chae, Doctor´s degree</last_name>
    <role>Principal Investigator</role>
    <affiliation>KuyngPook National Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KyungPook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>110-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>May 31, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>ARB</keyword>
  <keyword>Fimasartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

